⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

November 26, 2025Expert Review of NeurotherapeuticsOpen Access

Precision pain management: can delta opioid receptor (DOR) agonists outperform more traditional pain management strategies?

Joseph V. Pergolizzi Jo Ann LeQuang

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Delta opioid receptors (DOR) are Class A, G-protein-coupled receptors that couple to the inhibitory Gai/o/z subunit, and they represent a new frontier in analgesic drug development. Of all endog...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Pergolizzi et al. (2025) studied this question.

synapsesocial.com/papers/6ab38aba436113d3d6402ca7 https://doi.org/10.1080/14737175.2025.2595000

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1The efficacy and safety of lurasidone in adolescents with bipolar disorder: a up-to-date drug profileExpert Review of Neurotherapeutics · 2026
2Brain-computer interface technology for chronic pain managementExpert Review of Neurotherapeutics · 2026
3Acute anxiety states in emergency neuropsychiatry: diagnostic boundaries, time-sensitive mechanisms, and rapid-acting therapeutic strategiesExpert Review of Neurotherapeutics · 2026
4A disease-specific and denominator-aware perspective on high-frequency cervical spinal cord stimulationExpert Review of Neurotherapeutics · 2026
5Non-invasive neuromodulation after repetitive head impacts: current evidence and a precision framework for circuit-based rehabilitationExpert Review of Neurotherapeutics · 2026
6Trauma-focused cognitive behavioral therapy for peripartum-onset post-traumatic stress disorder: a narrative reviewExpert Review of Neurotherapeutics · 2026
7Recent advances in the management of Lewy body dementia: evaluating progress and future directionsExpert Review of Neurotherapeutics · 2026
8Diagnostic evolution of carbonic anhydrase 3 (CA3) in Amyotrophic Lateral Sclerosis (ALS): an emerging prognostic biomarkerExpert Review of Neurotherapeutics · 2026
9Current and emerging neuromodulation techniques for motor recovery after ischemic stroke: a 2026 updateExpert Review of Neurotherapeutics · 2026
10When sex matters early: clues from pediatric onset multiple sclerosisExpert Review of Neurotherapeutics · 2026

More from Expert Review of Neurotherapeutics

More from Nema Research (United States)